摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(2-chlorobenzyl)-2-[1-(2-methoxyphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-phenylethyl)acetamide | 439568-40-8

中文名称
——
中文别名
——
英文名称
N-(2-chlorobenzyl)-2-[1-(2-methoxyphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-phenylethyl)acetamide
英文别名
N-[(2-chlorophenyl)methyl]-2-[1-(2-methoxyphenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N-(2-phenylethyl)acetamide
N-(2-chlorobenzyl)-2-[1-(2-methoxyphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-phenylethyl)acetamide化学式
CAS
439568-40-8
化学式
C33H33ClN2O2
mdl
——
分子量
525.09
InChiKey
XZTDBFVTRYNMLZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    7.1
  • 重原子数:
    38
  • 可旋转键数:
    9
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    32.8
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS
    申请人:NEUROGEN CORPORATION
    公开号:EP1490044A1
    公开(公告)日:2004-12-29
  • EP1490044A4
    申请人:——
    公开号:EP1490044A4
    公开(公告)日:2008-04-16
  • [EN] COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS<br/>[FR] THERAPIE COMBINATOIRE POUR LE TRAITEMENT DE MALADIES FAISANT INTERVENIR DES COMPOSANTS INFLAMMATOIRES
    申请人:NEUROGEN CORP
    公开号:WO2003084524A1
    公开(公告)日:2003-10-16
    Compositions and methods for treating diseases that are associated with inflammation are provided. Such diseases include arthritis (particularly rheumatoid arthritis) and other autoimmune disorders, asthma, cardio-and cerebrovascular disease, burns, psoriasis, reperfusion injury, and traumatic CNS and spinal cord injury. The compositions generally comprise at least one C5a antagonist and at least one C5a receptor-inactive therapeutic agent. The methods involve co-administration of at least one C5a antagonist and at least one C5a receptor-inactive therapeutic agent to a patient. The C5a antagonist and C5a receptor-inactive therapeutic agent may be present within the same composition, or may be administered separately to the patient.
查看更多